Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma

Epigenetic alterations have emerged as essential contributors in the pathogenesis of various human diseases, including cutaneous melanoma (CM). Unlike genetic changes, epigenetic modifications are highly dynamic and reversible and thus easy to regulate. Here, we present a comprehensive review of the...

Full description

Bibliographic Details
Main Authors: Elena-Georgiana Dobre, Carolina Constantin, Marieta Costache, Monica Neagu
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Journal of Personalized Medicine
Subjects:
Online Access:https://www.mdpi.com/2075-4426/11/9/901
id doaj-c57f112123e34b1db0e743583203f7b7
record_format Article
spelling doaj-c57f112123e34b1db0e743583203f7b72021-09-26T00:32:07ZengMDPI AGJournal of Personalized Medicine2075-44262021-09-011190190110.3390/jpm11090901Interrogating Epigenome toward Personalized Approach in Cutaneous MelanomaElena-Georgiana Dobre0Carolina Constantin1Marieta Costache2Monica Neagu3Faculty of Biology, University of Bucharest, Splaiul Independentei 91–95, 050095 Bucharest, RomaniaImmunology Department, “Victor Babes” National Institute of Pathology, 050096 Bucharest, RomaniaFaculty of Biology, University of Bucharest, Splaiul Independentei 91–95, 050095 Bucharest, RomaniaFaculty of Biology, University of Bucharest, Splaiul Independentei 91–95, 050095 Bucharest, RomaniaEpigenetic alterations have emerged as essential contributors in the pathogenesis of various human diseases, including cutaneous melanoma (CM). Unlike genetic changes, epigenetic modifications are highly dynamic and reversible and thus easy to regulate. Here, we present a comprehensive review of the latest research findings on the role of genetic and epigenetic alterations in CM initiation and development. We believe that a better understanding of how aberrant DNA methylation and histone modifications, along with other molecular processes, affect the genesis and clinical behavior of CM can provide the clinical management of this disease a wide range of diagnostic and prognostic biomarkers, as well as potential therapeutic targets that can be used to prevent or abrogate drug resistance. We will also approach the modalities by which these epigenetic alterations can be used to customize the therapeutic algorithms in CM, the current status of epi-therapies, and the preliminary results of epigenetic and traditional combinatorial pharmacological approaches in this fatal disease.https://www.mdpi.com/2075-4426/11/9/901cutaneous melanomaepigenetic regulationinflammationdrug resistancebiomarkerstherapeutic targets
collection DOAJ
language English
format Article
sources DOAJ
author Elena-Georgiana Dobre
Carolina Constantin
Marieta Costache
Monica Neagu
spellingShingle Elena-Georgiana Dobre
Carolina Constantin
Marieta Costache
Monica Neagu
Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
Journal of Personalized Medicine
cutaneous melanoma
epigenetic regulation
inflammation
drug resistance
biomarkers
therapeutic targets
author_facet Elena-Georgiana Dobre
Carolina Constantin
Marieta Costache
Monica Neagu
author_sort Elena-Georgiana Dobre
title Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
title_short Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
title_full Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
title_fullStr Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
title_full_unstemmed Interrogating Epigenome toward Personalized Approach in Cutaneous Melanoma
title_sort interrogating epigenome toward personalized approach in cutaneous melanoma
publisher MDPI AG
series Journal of Personalized Medicine
issn 2075-4426
publishDate 2021-09-01
description Epigenetic alterations have emerged as essential contributors in the pathogenesis of various human diseases, including cutaneous melanoma (CM). Unlike genetic changes, epigenetic modifications are highly dynamic and reversible and thus easy to regulate. Here, we present a comprehensive review of the latest research findings on the role of genetic and epigenetic alterations in CM initiation and development. We believe that a better understanding of how aberrant DNA methylation and histone modifications, along with other molecular processes, affect the genesis and clinical behavior of CM can provide the clinical management of this disease a wide range of diagnostic and prognostic biomarkers, as well as potential therapeutic targets that can be used to prevent or abrogate drug resistance. We will also approach the modalities by which these epigenetic alterations can be used to customize the therapeutic algorithms in CM, the current status of epi-therapies, and the preliminary results of epigenetic and traditional combinatorial pharmacological approaches in this fatal disease.
topic cutaneous melanoma
epigenetic regulation
inflammation
drug resistance
biomarkers
therapeutic targets
url https://www.mdpi.com/2075-4426/11/9/901
work_keys_str_mv AT elenageorgianadobre interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma
AT carolinaconstantin interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma
AT marietacostache interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma
AT monicaneagu interrogatingepigenometowardpersonalizedapproachincutaneousmelanoma
_version_ 1717365922157559808